{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:51:03Z","timestamp":1787071863706,"version":"build-2736575974"},"reference-count":31,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuroepidemiology"],"abstract":"<jats:p>Introduction: Essential tremor (ET) carries a substantial burden and unmet need. Limited real-world evidence exists for the epidemiology, clinical characteristics, and treatment patterns of ET in the UK. We conducted a retrospective cohort study using a large electronic health records database from the UK. Methods: Data were obtained from Clinical Practice Research Datalink linked with Hospital Episode Statistics inpatient and outpatient databases from 1 January 2010 to 31 December 2022. Point prevalence and cumulative incidence were assessed, including age- and sex-standardized estimates to the Office for National Statistics mid-year population estimates. In a cohort of newly diagnosed ET patients (1 January 2011\u201331 March 2020), we evaluated baseline characteristics, clinical features, and treatment patterns. We used descriptive statistics as well as time-to-event analyses (Kaplan-Meier methodology). Results: Age-sex standardized prevalence ranged from 20.62 to 55.08 per 100,000 persons (2010\u20132021), peaking at 55.08 in 2019. Age-sex standardized cumulative incidence ranged from 3.85 to 6.81 per 100,000 persons (2011\u20132021), peaking at 6.81 in 2017. Common comorbidities included hypertension (23.43%), pain disorders (17.12%), and diabetes (15.64%). Most patients (86.07%) received at least one pharmacological therapy: propranolol (68.34%), primidone (27.68%), and gabapentin (22.14%) were most frequently used. Median time from diagnosis to treatment initiation was 0.43 months (95% confidence interval [CI]: 0.36\u20130.46); median time to discontinuation from start of first therapy was 4.63 months (95% CI: 4.27\u20135.19); median time to switch was 21.22 months (95% CI: 20.14\u201322.60). Conclusion: This study provides UK-based evidence on ET epidemiology, clinical features, and treatments. Despite lower epidemiological estimates attributable to the requirement for two confirmed diagnoses \u2013 a methodological choice prioritizing diagnostic specificity in a condition that is frequently overdiagnosed \u2013 ET burden and unmet needs remain substantial.<\/jats:p>","DOI":"10.1159\/000553098","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:01:01Z","timestamp":1783699261000},"page":"1-18","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and Treatment of Patients with Essential Tremor: A Retrospective Cohort Analysis in the United Kingdom"],"prefix":"10.1159","author":[{"given":"Tabish A.","family":"Saifee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keltie","family":"O&apos;Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evi","family":"Zhuleku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ghiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Dzimitrowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7970-6679","authenticated-orcid":false,"given":"Javier","family":"Sabater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Becktepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.632"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.11.04028"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00314-w"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4485"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000161852.70374.01"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.8.1100"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00172"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27121"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.04.1390"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.715"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26708"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1184"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27700"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4137\/jcnsd.s6561"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02318-8"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.59"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0753-5"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.987618"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130105"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510240012003"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.5.466"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.36469\/001c.37307"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000111584"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-11775-8"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd007938.pub4"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02926.x"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.239"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.39.12.1587"}],"container-title":["Neuroepidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000553098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:01:05Z","timestamp":1787068865000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000553098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1159\/000553098","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32955686","asserted-by":"subject"}]},"ISSN":["0251-5350","1423-0208"],"issn-type":[{"value":"0251-5350","type":"print"},{"value":"1423-0208","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}